RESULTS

Figure 1. Stably increases in proliferating, activated T cells observed in patients treated with PD-1/chemo.3A-F. Changes in circulating T cell subpopulations (CD3+ cells) in patients treated with PD-1/chemo were compared to historical control data. Results from the CD40/PD-1/chemo cohort are not shown. For cohorts B2 and C2, on Day 3 sotiga was administered. For cohorts A1 and C2, on Day 1 and Day 15, sotiga was administered.

Figure 2. CCR7 expression decreases on CD27- B cells from patient PBMCs treated with PD-1/chemo. For cohorts B2 and C2, on Day 3 sotiga was administered. For cohorts A1 and C2, on Day 1 and Day 15, sotiga was administered.

Figure 3. Legend below of Multidimensional

Figure 4. Principal Component Analysis (PCA) with variable scan of all the proteins included in the analysis PD-1/chemo: C1D1 (blue), C1D15 (red), C2D1 (purple), C2D15 (green) and C3D1 (brown). The LC-MS/MS data were acquired using Biognosys BiDear-3000, a high-performance liquid chromatography system equipped with a Biognosys BiDear-3000 mass spectrometer.

Figure 5. Absolute importance score for ST3GAL6, CSF1R and CD40/chemo.

Figure 6. Integrated analysis of on Treatment (C2D1) data across the grown and assays related to within temporal area. BM, Circulating B cells; Lin, lymphocytes; Lin+ T cells, CD3+ T cells; myeloid, CD14+ CD3+ cells.

REFERENCES


